Press Releases
All Pfizer published press releases by date and/or category of news
-
03.09.2022 Vaccines Covid-19 Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants -
03.08.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference -
03.02.2022 Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women -
03.01.2022 Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints -
02.28.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference -
02.25.2022 Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment -
02.22.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference -
02.15.2022 Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency -
02.15.2022 European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults -
02.14.2022 Research Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea -
02.11.2022 Covid-19 Vaccines Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age -
02.09.2022 Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Media Asset Library
A collection of assets for use by media.
Updates and Statements
Partnering News
The latest news from Pfizer and its strategic partners
-
06.22.2021 Partnerships SVI announces collaboration with Pfizer -
06.01.2021 Partnerships IMI SOPHIA PARTNERS WITH MACCABI’S RESEARCH AND INNOVATION CENTER (KSM), PFIZER, AND LAUSANNE UNIVERSITY HOSPITAL TO IMPROVE OBESITY TREATMENT
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.